Tofacent 5 mg is identified on this website as a product containing tofacitinib.
Product identity
| Product characteristic | Information |
|---|---|
| Product | Tofacent |
| Active ingredient | Tofacitinib |
| Stated strength | 5 mg |
| Drug class | Janus kinase inhibitor |
| Therapeutic category | Immunomodulatory medicine |
| Dosage form | 5 mg twice daily for adults |
| Route | oral |
| Reference product | XELJANZ |
| Original developer | Pfizer |
| Tofacent manufacturer | Incepta Pharmaceuticals Ltd. |
| Tofacent authorization | Incepta Pharmaceuticals Ltd. |
Tofacitinib inhibits JAK-dependent signaling involved in immune and inflammatory responses.
Therapeutic context
Tofacitinib is used in selected patients with inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis, with additional pediatric indications in current U.S. labeling.
Reference product
XELJANZ is the established reference product associated with Pfizer. The presence of the same active ingredient does not establish that Tofacent has the same formulation, manufacturing process, authorization or excipients.
Safety
Tofacitinib has important risks involving serious infection, malignancy, major cardiovascular events and thrombosis.
Product verification
The actual Tofacent package and supporting documentation should be checked before use. No Tofacent-specific authentication mechanism should be stated without evidence.